NCT05089643 2022-01-10
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
ChineseAMS
Phase 2 Unknown
Clinical Trials
5 trialsNCT04999800 2021-08-11
Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1
ChineseAMS
Phase 2 Unknown
NCT04452370 2021-07-21
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT04620837 2020-11-09
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
ChineseAMS
Phase 2 Unknown
NCT04002284 2020-07-29
Anlotinib in Metastatic HER2 Negative Breast Cancer
ChineseAMS
Phase 2 Completed